The drug slows functional decline in patients with mild disease and should be available to U.S. patients in August.
A trial of an α-synuclein antibody is making use of the technology to follow subtle changes in the day-to-day function of participants.
Even without this important sidekick at hand, scientists are forging ahead with efficacy trials of their first attempts at disease-modification in Parkinson’s
Electrodes entering the brain through a hole above the jaw detected epileptic spikes in the hippocampi of Alzheimer’s patients. Scalp recordings missed the action.
Animal models suggest excessive NFκB-TNFα signaling brings on compulsive behavior in a frontotemporal dementia mouse model and early death in flies.
Found in familial and sporadic cases of ALS, mutations in the annexin A11 gene lead to elaborate protein clumps and seem to disrupt vesicular trafficking.
People with ALS—especially those who progress fast—express myriad inflammatory genes in their blood monocytes.
Congress has opposed the Trump administration’s request to cut NIH funding, agreeing on a $2 billion boost, with a $400 million bonus for Alzheimer’s research.
Using torpedo-like DNA snippets to delete mRNAs from cells, scientists lowered the amount of ataxin-2 protein. This allayed disease in mouse models of two neurodegenerative disorders.
The microbial communities teeming in the intestine of people recently diagnosed with PD differed markedly from those of healthy controls.
Three anti-tau antibodies are in Phase 1 or 2, while an O-GlcNAcase inhibitor got the green light to start testing.
Manufacturers of a therapy system called neuroAD, which combines transcranial magnetic stimulation with cognitive training, are applying for FDA marketing clearance.
NIH Summit Examines What Makes a Healthy Aging Brain ...
Overexpressing miR-132 dampened AD pathology in young mice, and appeared to nourish the birth of new hippocampal neurons in older animals.
As the brain ages, what protects it from cognitive decline? A two-day conference focused on reserve and resilience.